Current FDA commissioner, Robert Califf, joins the show to cover his story – from his career path to his crucial role today. Join Chadi in this eye-opening episode as they uncover the complexities of drug shortages in the United States, especially in the realm of cancer treatment.
Learn about the intricate web of factors contributing to drug shortages, how cancer drug scarcities emerged, and the FDA’s pivotal role in addressing them. Dr. Califf shares strategies to mitigate these issues, emphasizing the importance of supply chain nuances and more.
Tune in to gain unique insights into the FDA’s commitment to patients and the future of cancer care.
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
